SCHEMBL13629427

SCHEMBL13629427

CCc1ccc(NS(=O)(=O)c2c(Cl)cccc2Cl)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
LMNA P02545 3/20 0.54
ATM Q13315 1/20 0.51
GAA P10253 1/20 0.49
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 3/20 0.46
PKM P14618 3/20 0.46
MCL1 Q07820 1/20 0.43
THRB P10828 1/20 0.42
HTT P42858 1/20 0.42
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
AXL P30530 1/20 0.40
IDH1 O75874 1/20 0.39
SCN1A P35498 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN8A Q9UQD0 1/20 0.39
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629312 0.85 ALDH1A1 (0.58) ALDH1A1LMNAMEN1KMT2ATHRB
SCHEMBL13629338 0.85 SLC22A12 (0.53) ALDH1A1LMNAGAAMEN1KMT2A
SCHEMBL13629424 0.84 ALDH1A1 (0.62) ALDH1A1LMNAATMGAAMEN1
SCHEMBL13629418 0.81 PKM (0.61) ALDH1A1LMNAMAPTPKM
SCHEMBL13615209 0.80 ALDH1A1 (0.50) ALDH1A1LMNAATMGAAMEN1
SCHEMBL13629403 0.79 CES1 (0.58) ALDH1A1LMNAGAAMEN1KMT2A
SCHEMBL13629298 0.79 MEN1 (0.49) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL13629296 0.78 ALDH1A1 (0.57) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL13629411 0.78 PPARG (0.55) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL13629290 0.78 BRD4 (0.52) ALDH1A1MAPTTHRBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2057/4885LMNA 2891/4885ATM 564/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2121/4885LMNA 2608/4885ATM 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.